Akoya Biosciences Inc (AKYA) Growth Rates Comparisons to Laboratory Analytical Instruments Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Akoya Biosciences Inc   (NASDAQ: AKYA)
 

Akoya Biosciences Inc Growth Comparisons

Select each growth Category to receive further Information





AKYA Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q1 MRQ) -8.68 % -0.41 % 3.99 % 4.2 %
Q / Q Revenue Growth (Q1 MRQ) -29.11 % -12.89 % -5.34 % -3.92 %
Y / Y Revenue Growth (for 12 months ending Q1 TTM) -13.03 % 2.37 % 5.43 % %
Sequential Revenue Growth (for 12 months ending Q1 TTM) -1.86 % -0.1 % 0.76 % 1.07 %
Revenue 5 Year Average Growth - 2.3 % 10.99 % 7.73 %


AKYA's Growth Comparisons in I. Quarter 2025




Although the Laboratory Analytical Instruments industry saw Revenue decrease just by -0.41%, Akoya Biosciences Inc announced -8.68% year on year sales decline in the first quarter 2025, to $ 16 millions, and underperformed the 3.99% Revenue growth in the Healthcare sector. Weak first quarter sales, in Laboratory Analytical Instruments industry and within the Healthcare sector, were reflected in Akoya Biosciences Inc results which underperformed overall market.

Top-line fell by -29.11% from the fourth quarter results. Comparing the annual growth, sales of % on average in last five years, to the S & P 500's, including only Businesses with the first quarter 2025 financial results, average yearly sales growth is 7.73%. Akoya Biosciences Inc grew less than the market.

AKYA Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Single reportable segment
-9.32 %
-
North America
0.14 %
-
APAC
-20.95 %
-
EMEA
-20.98 %
-
Total
-13.51 %
-80.38 %


Growth Rates of AKYA's Income in the first quarter 2025


AKYA Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q1 MRQ) - -19.4 % 98.32 % 2.39 %
Sequential Operating Income Change (Q1 MRQ) - -72.88 % 29.36 % 12.67 %
Y / Y Operating Income Growth (Q1 TTM) - 67.01 % 77.41 % 6.79 %
Sequential Operating Income Growth (Q1 TTM) - -3.24 % 17.31 % 0.65 %
Operating Income 5 Year Avg. Change - -7.66 % -0.96 % 9 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q1 MRQ) - -76.81 % 254.08 % 14.03 %
Sequential Income from Cont. Ops. Change (Q1 MRQ) - -77.86 % 3992.22 % 0.54 %
Y / Y Income from Cont. Ops. Change (Q1 TTM) - - 146.7 % 13 %
Sequential Income from Cont. Ops. Change (Q1 TTM) - - 14.55 % 2.54 %
Income from Cont. Ops. 5 Year Avg. Change - - -17.93 % 8.34 %

AKYA Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q1 MRQ) - -76.63 % 257.84 % 13.51 %
Q / Q Net Income Growth (Q1 MRQ) - -79.85 % 19.03 % -0.08 %
Y / Y Net Income Change (Q1 TTM) - - 57.78 % 11.01 %
Sequential Net Income Change (Q1 TTM) - - 23.6 % 2.45 %
Net Income 5 Year Avg. Growth - - 6.2 % 9.47 %

AKYA's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q1 MRQ) - -76.97 % 254.08 % 14.03 %
Sequential EPS from Cont. Ops. Change (Q1 MRQ) - -77.06 % 3992.22 % 0.54 %
Y / Y EPS from Cont. Ops. Change (Q1 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q1 TTM) - - - -23.98 %
EPS from Cont. Ops. 5 Year Avg. Growth - - -17.93 % 8.34 %



AKYA EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q1 MRQ) - -76.78 % 257.84 % 8.34 %
Q / Q EPS Net Growth (Q1 MRQ) - -79.11 % 19.03 % -0.08 %
Y / Y EPS Net Change (for 12 months ending Q1 TTM) - - - 0.14 %
Sequential EPS Net Change (for 12 months ending Q1 TTM) - - - -23.99 %
EPS Net 5 Year Avg. Change - - 6.2 % 9.47 %



Akoya Biosciences Inc reported bottom-line of $ -0.32 in the first quarter, compare to $ -0.48 in the same quarter a year ago. Laboratory Analytical Instruments industry fell by -76.78%, while Healthcare sector increased by 257.84%, and overall market improved by 13.51%.

Bottom-line fell by -29.11% from the fourth quarter results. Comparing the annual growth, income per share of % on average in last five years, to the S & P 500's, including only Businesses with the first quarter 2025 earnings, average yearly income per share growth is 9.47%. Akoya Biosciences Inc grew less than the market.

AKYA Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q1 MRQ) - - -2.89 % -92.81 %
Sequential Free Cash Flow Change (Q1 MRQ) - -54.31 % -70.2 % -98.71 %
Y / Y Free Cash Flow Change (Q1 TTM) - 21.96 % 27.33 % 7.78 %
Sequential Free Cash Flow Change (Q1 TTM) - 3.75 % 7.43 % -2.25 %
Free Cash Flow 5 Year Avg. Change - 5.33 % 6.34 % 10.76 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q1 MRQ) - - - -
Sequential Net Cash Flow Change (Q1 MRQ) - 43.25 % - -
Y / Y Net Cash Flow Change (Q1 TTM) - - -80.31 % -
Sequential Net Cash Flow Change (Q1 TTM) - - -59.61 % -
Net Cash Flow 5 Year Avg. Change - - -1.7 % -32.35 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q1 MRQ) -74.81 % 78.96 % 6.89 % 18.29 %
Sequential Capital Expenditures Change (Q1 MRQ) -80.42 % -10.96 % -19.49 % -17.95 %
Y / Y Capital Expenditures Change (Q1 TTM) -49.44 % -2.62 % 7.83 % 39.53 %
Sequential Capital Expenditures Change (Q1 TTM) -24.67 % -0.1 % 4.13 % 5.69 %
Capital Expenditures 5 Year Avg. Change - 5.74 % 9 % 10.74 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.